Experience with International Neuroblastoma Staging System and Pathology Classification by Ikeda, H et al.
Experience with International Neuroblastoma Staging System and
Pathology Classiﬁcation
H Ikeda
1, T Iehara
2, Y Tsuchida*
,3, M Kaneko
4, J Hata
3, H Naito
3, M Iwafuchi
3, N Ohnuma
3, H Mugishima
3,
Y Toyoda
3, M Hamazaki
3, J Mimaya
3, S Kondo
3, K Kawa
3, A Okada
3, E Hiyama
3, S Suita
3 and H Takamatsu
3
1Department of Pediatric Surgery, Dokkyo University School of Medicine, Koshigaya Hospital, 2-1-50 Minami-Koshigaya, Koshigaya, Saitama 343-8555, Japan;
2Department of Pediatrics, Kyoto Prefectural University of Medicine, Hirokohji, Kawaramachi-dori, Kamigyo-ku, Kyoto 602-8566, Japan;
3Study Group of
Neuroblastoma, Gunma Children’s Medical Center, 377 Shimohakoda, Hokkitsu, Seta-gun, Gunma 377-8577, Japan;
4Department of Pediatric Surgery,
University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan
The International Neuroblastoma Staging System and Pathology Classiﬁcation were proposed in 1988 and in 1999, respectively,
but their clinical value has not yet been fully studied in new patients. Six hundred and forty-four patients with neuroblastoma
treated between January 1995 and December 1999 were analysed by these classiﬁcations. The 4-year overall survival rate of
patients 512 months of age with INSS stages 1, 2A, 2B, 3 and 4S disease was 98.5%, which was signiﬁcantly higher than the
73.1% rate in stage 4 patients 512 months (P50.0001). When patients were 512 months, the 4-year overall survival rate of
patients with neuroblastoma at 1, 2A, 2B and 3 stages was 100% and that of patients at stage 4 was 48.5% (P50.0001). As to
the International Neuroblastoma Pathology Classiﬁcation histology, the 4-year overall survival rate was 98.8% in patients with
favourable histology and 60.7% in those with unfavourable histology in the 512 months group (P50.0001). In the 512
months group, the 4-year oral survival of patients with favourable histology was 95.3% and that of patients with unfavourable
histology was 50.6% (P50.0001). Among biological factors, MYCN ampliﬁcation, DNA diploidy and 1p deletions were
signiﬁcantly associated with poor prognosis in patients 512 months, as were MYCN ampliﬁcation and DNA diploidy in patients
512 months of age. Multivariate analysis showed that the INSS stage (stage 4 vs other stages) and International Neuroblastoma
Pathology Classiﬁcation histology (unfavourable vs favourable) were signiﬁcantly and independently associated with the survival
of patients undergoing treatment, stratiﬁed by age, stage and MYCN ampliﬁcation (P=0.0002 and P=0.0051, respectively).
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International cooperative groups have developed new classiﬁcations
of neuroblastoma risk groups to compare treatment results interna-
tionally and seek effective means to deal with neuroblastoma,
particularly in advanced stages. The International Neuroblastoma
Staging System (INSS) was originally proposed in 1988, and revised
in 1993 (Brodeur et al, 1993). Since then the INSS has been used
worldwide (Castleberry et al, 1994; Kaneko et al, 1998), replacing
the previous staging systems of different groups. The International
Neuroblastoma Pathology Classiﬁcation (INPC) that is fundamen-
tally based on Shimada’s classiﬁcation was also proposed in 1999 to
provide neuroblastoma study groups with a common language
(Shimada et al, 1999). However, the clinical importance of these
classiﬁcations has never been extensively evaluated; Castleberry et
al (1994) applied the INSS only retrospectively for their patients
treated between 1981 and 1990. Since the predictability of prognos-
tic factors often depends on the intensity or efﬁcacy of treatment, it
is important to examine the value of these risk classiﬁcations in a
study in which highly effective modern treatments are applied
(Kawa et al, 1999; Matthay et al, 1999).
Clinical results achieved prior to 1991 by us and by others
(Brodeur et al, 1984; Seeger et al, 1985; Sawaguchi et al, 1990)
clearly showed that patients with MYCN-ampliﬁed tumours have
a worse prognosis than those without. It was therefore decided
in Japan in 1991 to administer intensive induction chemotherapy
with a double dose of cyclophosphamide to high-risk patients with
MYCN ampliﬁcation (Kaneko et al, 1998), and that strategy
resulted in improved clinical results (Kawa et al, 1999). In the
present study we examined the prognostic value of the INSS, the
INPC and biological factors including MYCN ampliﬁcation, DNA
ploidy and 1p deletion in patients with neuroblastoma who under-
went treatment between 1995 and 1999.
PATIENTS AND METHODS
A total of 731 patients with newly diagnosed neuroblastoma whose
treatment was started between January 1995 and December 1999
were retrospectively reviewed. Patients 512 months of age were
treated with the protocols for advanced neuroblastoma in which
treatment was stratiﬁed by stage and MYCN ampliﬁcation status
(Kaneko et al, 1998). Stem cell transplantation was performed in
65.4% of stage 4 patients and in 67.4% of MYCN-ampliﬁed
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registered with the Japanese Infantile Neuroblastoma Cooperative
Study and were treated with the protocols for infant neuroblastoma
(Matsumura and Michon, 2000). Brieﬂy, these infant patients were
ﬁrst examined for the presence or absence of MYCN ampliﬁcation,
and those without ampliﬁcation were treated with or without
chemotherapy based on the INSS stage. Patients with MYCN
ampliﬁcation were treated, like patients 512 months of age, with
combination chemotherapy with or without stem cell transplanta-
tion. Stem cell transplantation was carried out in 27.5% of stage 4
patients and in 41.7% of MYCN-ampliﬁed patients 512 months of
age (Table 1).
Patient information with regard to age, gender, stage, histology
and biological characteristics of the tumour including MYCN
ampliﬁcation, DNA ploidy and 1p deletion was collected from
the participating institutions (Appendix). Two pathologists, one
of whom was a member of the International Neuroblastoma
Pathology Committee, reviewed all of the specimens according to
the INPC (Shimada et al, 1999). The MYCN gene copy number
was determined by Southern blot hybridisation, and ampliﬁcation
was deﬁned as 510 copies. DNA content analysis was performed
by means of ﬂow cytometry, and tumours were classiﬁed into
diploid tumours (DNA index=1) and aneuploid tumours (DNA
index 51.1). No genes responsible for MYCN ampliﬁcation have
yet been identiﬁed and there is no consensus on the deﬁnition
of prognostically signiﬁcant deletions of 1p so that no single
uniform method to detect 1p deletions could be used. The method
was therefore left to the discretion of each laboratory, and 1p dele-
tions were deﬁned as present when karyotypic analysis showed
large deletions in the distal region of 1p or when molecular analysis
demonstrated small deletions of 1p36 by examining the loss of
heterozygosity (LOH) with gene markers (Ohtsu et al, 1997).
Patient outcomes were followed up as of 30 September 2000,
and the results were obtained in 675 patients. There were 31
patients with screening-detected tumours who had been observed
without histological conﬁrmation and deﬁnitive treatment. Exclud-
ing these 31 patients because of insufﬁcient data, 644 patients, 368
males and 276 females, were included in the ﬁnal analyses. The age
of the patients ranged from 0 to 221 months (median, 8 months),
and 485 patients were 512 months of age with 159 patients 512
months.
Differences between the two groups in categorical data were
analysed by means of Fisher’s exact probability test or the chi-
square test. Overall survival was estimated by the Kaplan-Meier
method and the difference between the curves was compared with
the log-rank test. For multivariate analysis, the Cox regression
models were used to identify independent prognostic factors.
Statistical analysis was performed with SPSS 7.5J for Windows
Medical Pack (SPSS Inc., Chicago, IL, USA) and a P value of
50.05 was considered statistically signiﬁcant.
RESULTS
INSS, INPC and biological prognostic factors
The INSS stage, INPC histology and biological prognostic factors
of the 644 patients are shown in Table 2. INSS stage was deter-
mined in 639 patients, and there was a signiﬁcant difference in
stage distribution between patients 512 months of age and those
512 months (P50.001). Among the 480 patients 512 months
of age, 43 (9%) had stage 4 disease, and there were 106 (67%)
stage 4 patients among the 159 patients 512 months. Histology
was evaluated according to the INPC in 556 patients. Of 423
patients 512 months of age, favourable histology was diagnosed
in 402 patients (95%) and unfavourable histology in 21 patients
(5%). Among the 133 patients 512 months of age, 47 patients
(35%) had favourable histology and 86 patients (65%) unfavour-
able histology. The difference between the two age groups in
unfavourable histology was statistically signiﬁcant (P50.001).
The occurrence of unfavourable biological characteristics was
also signiﬁcantly different between 512 months and 512 months
of age. The MYCN gene copy number was examined in 609
patients. Greater than 510 copies of MYCN were observed in 14
(3%) of 457 patients 512 months of age, and in 46 (30%) of
152 patients 512 months (P50.001). DNA content analysis by
ﬂow cytometry was carried out in 480 patients and 78 (21%) of
375 patients in the younger age group and 55 (52%) of 105
patients in the older age group had diploid tumours (P50.001).
Chromosomal abnormalities were examined in 361 patients, and
the presence of 1p deletions was demonstrated in 24 (9%) of
262 patients 512 months of age and in 29 (29%) of 99 patients
512 months (P50.001).
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Table 1 Number of patients who received stem cell transplantation
according to sub-groups
Stem cell
transplantation
Age Sub-groups Received Not-received No information
512 months Stage 1, 2A, 2B, 3, 4S 3 428 6
(n=485) Stage 4 11 (27.5%) 29 3
not determined 0 5 0
MYCN 510 copies 9 427 7
MYCN 510 copies 5 (41.7%) 7 2
not determined 0 28 0
512 months Stage 1, 2A, 2B, 3 4 49 0
(n=159) Stage 4 68 (65.4%) 36 2
MYCN 510 copies 35 70 1
MYCN 510 copies 31 (67.4%) 15 0
not determined 0 6 1
Table 2 INSS, INPC and biological characteristics by age in 644 patients
with neuroblastoma
Patient age
512 months 512 months
Characteristics (n=485) (n=159) Total P value
INSS
1 217 (45%) 26 (16%) 243
2A 38 (8%) 5 (3%) 43
2B 69 (14%) 7 (4%) 76 50.001
3 73 (15%) 15 (9%) 88
4 43 (9%) 106 (67%) 149
4S 40 (8%) 40
ND 5 5
INPC
Favourable 402 (95%) 47 (35%) 449
Unfavourable 21 (5%) 86 (65%) 107 50.001
ND 62 26 88
MYCN
510 copies 443 (97%) 106 (70%) 549
510 copies 14 (3%) 46 (30%) 60 50.001
ND 28 7 35
DNA ploidy
Aneuploidy 297 (79%) 50 (48%) 347
Diploidy 78 (21%) 55 (52%) 133 50.001
ND 110 54 164
1p deletion
7ve 238 (91%) 70 (71%) 308
+ve 24 (9%) 29 (29%) 53 50.001
ND 223 60 283
INSS=International Neuroblastoma Staging System; INPC=International Neuroblas-
toma Pathology Classiﬁcation; ND=not determined; 7ve=negative; +ve=positive.
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The median follow-up for all of the 644 patients was 1120 days,
and that for living patients 1179 days. The 2- and 4-year overall
survival (2-OS and 4-OS) rates of patients 512 months of age
were 96.5 and 96.2%, respectively, and those of patients who were
512 months of age were 77.6 and 64.6%, respectively. Seventy-ﬁve
per cent of the patients in this series were 512 months of age. To
avoid the bias relating to the patient age distribution, the following
data analyses were performed in two groups of 512 months and
512 months of age.
The 2-OS and 4-OS rates of the 639 patients are shown accord-
ing to the INSS stage in Table 3. There were no differences in the
overall survival rates among stages 1, 2A, 2B, 3 and 4S patients
512 months of age, and none among stages 1, 2A, 2B and 3
patients 512 months of age, either. Therefore, infants with stages
1, 2A, 2B, 3 and 4S disease in the younger age group, and patients
with stages 1, 2A, 2B and 3 disease in the older age group were
combined in the subsequent survival analyses.
In patients 512 months of age, the 4-OS rate of patients in
stages 1, 2A, 2B, 3 and 4S combined was 98.5%, which was signif-
icantly higher than the 73.1% of patients in stage 4 (P50.0001). In
patients 512 months of age, the 4-OS rate of patients in stages 1,
2A, 2B and 3 combined was 100%, whereas that of patients with
stage 4 disease was 48.5%; the difference was statistically signiﬁcant
(P50.0001) (Figure 1).
INPC histology was also shown to be a signiﬁcant prognostic
factor. The 4-OS rate of patients with favourable histology was
98.8%, signiﬁcantly higher than the rate of 60.7% for patients with
unfavourable histology when the patients were 512 months of age
(P50.0001) (Figure 2). The survival rate for patients with favour-
able histology was 95.3%, signiﬁcantly higher than the 50.6% rate
for patients with unfavourable histology in patients 512 months of
age (P50.0001).
Among patients 512 months of age, overall survival rates
for patients with favourable biological characteristics (510
copies of the MYCN gene, aneuploidy and absence of 1p dele-
tions) were signiﬁcantly higher than those for patients with
unfavourable characteristics (510 copies of the MYCN gene,
diploidy and the presence of 1p deletions) (Figures 3, 4 and
5, respectively) (P50.0001, P=0.0007 and P50.0001, respec-
tively). Of the 14 patients with MYCN ampliﬁcation, eight
patients had died before this retrospective review, and the 4-
OS rate was 40.8%.
When the patients were 512 months of age, MYCN ampliﬁ-
cation and DNA diploidy were signiﬁcantly associated with
poor prognosis. The 2-OS and 4-OS rates for patients with
neuroblastoma with ampliﬁed MYCN were 67.1 and 54.4%,
respectively, and signiﬁcantly lower than the 83.8 and 72.0%
for patients without MYCN ampliﬁcation (P=0.0117). The 2-OS
and 4-OS rates for patients with diploid tumour were 77.4 and
61.5%, respectively, which were signiﬁcantly lower than the 93.4
and 84.2%, respectively, for patients with aneuploid tumour
(P=0.0256). In the overall survival rate there was no signiﬁcant
difference between patients with and without 1p deletion
(P=0.1148).
Multivariate analysis of prognostic factors
A multivariate analysis with Cox regression models was undertaken
in 460 patients with complete data including age, INSS stage, INPC
histology, MYCN ampliﬁcation and DNA ploidy (Table 4). 1p dele-
tion was excluded from the analysis because genetic abnormalities
of chromosome 1p were examined in only 361 (56.1%) of 644
patients. The analysis showed that INSS stage and INPC histology
were signiﬁcantly and independently associated with patient survi-
val (P=0.0002 and P=0.0051, respectively), and that the biological
variables, MYCN ampliﬁcation and DNA ploidy, did not have
prognostic signiﬁcance after correcting for stage and histology by
the INSS and INPC.
DISCUSSION
A protocol with stratiﬁcation of treatment mainly based on the
presence or absence of MYCN ampliﬁcation was introduced in
our group study in 1991 (Kaneko et al, 1998). This protocol was
designed to administer intensive induction chemotherapy with a
double dose of cyclophosphamide and to do stem cell transplanta-
tion to high-risk patients with MYCN ampliﬁcation, and analysis of
outcomes showed a signiﬁcantly higher response rate and a
number of long-term survivors in patients with MYCN ampliﬁca-
tion (Kawa et al, 1999). For infantile neuroblastomas, another
group study was started in 1994, and the protocol was revised in
1998 (Matsumura and Michon, 2000).
The INSS is a surgicopathologic staging system and the chief
difference between it and the Evans staging system is the deﬁnition
of stage of locoregional disease (Evans et al, 1971; Brodeur et al,
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Table 3 Two- and four-year overall survival rates by various factors
Overall survival rate
(%)
Factor n 2-year 4-year P value
INSS stage
512 months
1 217 99.5 99.5
2A 38 100 100
2B 69 98.4 98.4
3 73 98.6 96.3 50.0001
4S 40 95.0 95.0
4 43 73.1 73.1
512 months
1 26 100 100
2A 5 100 /
2B 7 100 100 50.0001
3 15 100 100
4 106 67.3 48.5
INPC histology
512 months
Favourable 402 98.8 98.8
Unfavourable 21 60.7 60.7 50.0001
512 months
Favourable 47 95.3 95.3
Unfavourable 86 70.3 50.6 50.0001
MYCN
512 months
510 copies 443 98.2 97.9
510 copies 14 40.8 40.8 50.0001
512 months
510 copies 106 83.8 72.0
510 copies 46 67.1 54.4 0.0117
DNA ploidy
512 months
Aneuploidy 297 98.0 98.0
Diploidy 78 89.2 89.2 0.0007
512 months
Aneuploidy 50 93.4 84.2 0.0256
Diploidy 55 77.4 61.5
1p deletion
512 months
7ve 238 99.2 98.6
+ve 24 82.9 82.9 50.0001
512 months
7ve 70 79.6 70.1
+ve 29 75.2 42.5 0.1148
7ve=negative; +ve=positive; /=not enough patients.
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difference in survival rate between the stages of localised disease.
The 4-OS rate for patients 512 months of age with stages 1,
2A, 2B, 3 and 4S disease was 98.5% and that for patients 512
months with stages 1, 2A, 2B and 3 disease was 100% (Table 3).
On the other hand, the survival rate in patients with metastatic
disease (excluding stage 4S) was signiﬁcantly worse than in patients
with non-metastatic disease, as reported by others (Hero et al,
2000). Previously, differences in survival rates among individual
stages were clear (Breslow and McCann, 1971; Matthay et al,
1998). Breslow and McCann (1971) demonstrated that the prog-
nosis for children with neuroblastoma becomes worse in the
order stage I, stage IVS, stage II, stage III and stage IV, with coefﬁ-
cients of 1.684, 0.661, 0.431, 70.092 and 72.684, respectively.
Matthay et al (1998) found that the survival rate for stage III
patients 512 months of age treated between 1991 and 1995 was
still worse than for stage III patients 512 months of age
(P=0.01). Our follow-up period is shorter than in other studies,
and the number of patients in the older age group was rather
small; especially there being only 15 patients 512 months of age
with stage 3 disease in the present study, which indicated that there
was no difference in the survival rate between stage 3 disease and
combined stages 1, 2A and 2B disease in patients 512 months
of age treated between 1995 and 1999. Among these 15 patients
512 months of age in stage 3, there were ﬁve patients with unfa-
vourable INPC and two patients with MYCN ampliﬁcation. One
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
1, 2, 3, 4S
4
<12 months
0         1         2         3         4         5         6         7 
Years
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
³12 months
0         1         2         3         4         5         6         7 
Years
1, 2, 3
4
Figure 1 Cumulated overall survival rates are shown. In patients 512 months of age, the 2- and 4-year overall survival rates for patients in stages 1, 2A,
2B, 3 and 4S combined (n=437) were 98.8 and 98.5%, respectively, which were signiﬁcantly higher than the 73.1 and 73.1% for patients in stage 4 (n=43)
(P50.0001). In patients 512 months of age, the 2- and 4-OS rates for patients in 1, 2A, 2B and 3 stages combined (n=53) were 100 and 100%, while those
for patients in stage 4 (n=106) were 67.3 and 48.5%, respectively (P50.0001).
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Figure 2 Cumulated overall survival rates for patients 512 months of age and 512 months of age are shown. The 2- and 4-OS rates for patients with
favourable histology (n=402) were 98.8 and 98.8%, respectively, signiﬁcantly higher than the rates of 60.7 and 60.7% for patients with unfavourable histology
(n=21) when the patients were 512 months of age (P50.0001). The 2- and 4-OS rates for patients with favourable histology (n=47) were 95.3 and 95.3%,
respectively, signiﬁcantly higher than the corresponding rates of 70.3 and 50.6% for patients with unfavourable histology (n=86) in patients 512 months of
age (P50.0001).
Table 4 Multivariate Cox regression analysis of 460 neuroblastoma
patients with complete data on age, stage, histology, MYCN status and
DNA ploidy
Factor Exp(B) 95% CI P
Age (512 months vs 512 months) 0.78 0.34–1.75 0.5431
INSS (4 vs others) 10.26 2.99–35.25 0.0002
INPC (unfavourable vs favourable) 5.79 1.69–19.76 0.0051
MYCN (510 copies vs 510 copies) 1.40 0.68–2.89 0.3642
DNA ploidy (diploidy vs aneuploidy) 0.83 0.39–1.74 0.6185
CI=conﬁdence interval; INSS=International Neuroblastoma Staging System;
INPC=International Neuroblastoma Pathology Classiﬁcation. Values are determined
by multivariate analysis with the Cox regression models.
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Figure 3 Cumulated overall survival rates for patients 512 months of age and 512 months of age are shown. Among patients 512 months of age, the
2- and 4-year overall survival rates for patients with 510 copies of MYCN (n=443) were 98.2 and 97.9%, respectively, which were signiﬁcantly higher than
the 40.8 and 40.8% for patients with 510 copies of MYCN (n=14) (P50.0001). In patients 512 months of age, the 2- and 4-OS rates for patients with
510 copies of MYCN (n=106) were 83.8 and 72.0%, respectively, whereas those of patients with 510 copies of MYCN (n=46) were 67.1 and 54.4%,
respectively (P=0.0117).
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Figure 4 Cumulated overall survival rates for patients 512 months of age and 512 months of age are shown. Among patients 512 months of age, the
2- and 4-year overall survival rates for patients with aneuploidy (n=297) were 98.0 and 98.0%, respectively, which were signiﬁcantly higher than the 89.2 and
89.2% for patients with diploidy (n=78) (P=0.0007). In patients 512 months of age, the 2- and 4-OS rates for patients with aneuploidy (n=50) were 93.4
and 84.2%, respectively, while those for patients with diploidy (n=55) were 77.4 and 61.5%, respectively (P=0.0256).
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Figure 5 Cumulated overall survival rates for patients 512 months of age and 512 months of age are shown. Among patients 512 months of age, the
2- and 4-year overall survival rates for patients without 1p deletion (n=238) were 99.2 and 98.6%, respectively, which were signiﬁcantly higher than the 82.9
and 82.9% for patients with 1p deletion (n=24) (P50.0001). In patients 512 months of age, the 2- and 4-OS rates for patients without 1p deletion (n=70)
were 79.6 and 70.1%, respectively, whereas those for patients with it (n=29) were 75.2 and 42.5%, respectively (P=0.1148).
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14 were disease free. We therefore would like to consider that this
implies some progress in treatment.
The INPC (Shimada et al, 1999) distinguished prognostic groups
clearly. Previous studies showed that the histological group
provides additional prognostic information beyond factors such
as age, stage and MYCN oncogene status (Suita et al, 1994; Rubie
et al, 1997; Matthay et al, 1998). The results of this study indicate
that INPC histology is a powerful and independent predictor of
prognosis.
MYCN ampliﬁcation in neuroblastoma is associated with
advanced stage, rapid tumour progression and poor prognosis
(Seeger et al, 1985; Suita et al, 1994; Combaret et al, 1996). Never-
theless, there is controversy over the prognostic importance of
MYCN in localised neuroblastoma. For example, it was shown that
patients who have stage 2 neuroblastoma with MYCN ampliﬁcation
are at higher risk than those without it (Rubie et al, 1997; Alvarado
et al, 2000; Perez et al, 2000), but another study demonstrated that
the presence of MYCN ampliﬁcation in localised neuroblastoma
does not necessarily indicate an adverse outcome (Cohn et al,
1995). In the present study, the presence of MYCN ampliﬁcation
was a signiﬁcant predictor of poor prognosis both in patients
512 months and 512 months of age. Eight of 14 patients with
MYCN ampliﬁcation died within 2 years after diagnosis in the
group of patients 512 months of age, and the 4-OS rate of
patients with MYCN ampliﬁcation was only 54.4% in the patients
512 months of age, whereas the 4-OS rate was 72.0% in patients
without MYCN ampliﬁcation in the same age group. Nevertheless,
multivariate analysis showed that MYCN ampliﬁcation is not an
independent prognostic factor. The lack of signiﬁcance of MYCN
ampliﬁcation as an independent prognostic factor is certainly asso-
ciated with improved survival for patients with MYCN
ampliﬁcation that was achieved by stratiﬁcation of treatment with
high-dose chemotherapy and blood stem cell transplantation (Kawa
et al, 1999). It shows, perhaps, that there was some success with the
treatment approach, not that MYCN has lost importance as a prog-
nostic factor.
DNA ploidy has been considered to be another signiﬁcant prog-
nostic predictor (Look et al, 1991), but the difference in survival
between the patients with diploid tumours and those with aneu-
ploid tumours was not great. The 4-OS rates in patients with
aneuploid tumours and with diploid tumours were 98.0 and
89.2%, respectively, among patients 512 months of age, and
84.2 and 61.5%, respectively, in patients 512 months of age.
These results appear to support the ﬁndings of Look and associ-
ates (Look et al, 1991) that demonstrated a close correlation
between tumour ploidy and outcome in a large series of patients
524 months of age, but not in older patients with metastatic
neuroblastoma.
1p deletion was a signiﬁcant predictor of prognosis in our
patients 512 months of age, but not in patients 512 months. This
result is comparable to the results from a study (Maris et al, 2000)
in which LOH at 1p36 predicted progression free survival, but not
decreased overall survival in patients with single copy of MYCN.
Tumour suppressor genes responsible for the development of
neuroblastoma are assumed to be present on chromosome 1p36,
but no conclusive results on the identiﬁcation and location of such
genes for LOH analysis have yet been reported. In this study, 1p
deletion was deﬁned when either karyotype analysis or screening
for 1p36 LOH (Ohtsu et al, 1997) showed such deletions as
described above. Important genetic abnormalities might not have
been detected, which in turn would have affected survival analysis.
A number of factors that correlate with the response to treat-
ment and outcome of patients with neuroblastoma have been
identiﬁed, including patient age, stage, histology, MYCN ampliﬁca-
tion, DNA ploidy, 1p deletions, 17q gain (Meddeb et al, 1996;
Bown et al, 1999), TRKA expression (Nakagawara et al, 1993;
Suzuki et al, 1993) and CD44 cell-surface expression (Combaret
et al, 1996). This study evaluated the prognostic importance of
the ﬁrst six factors that are generally considered essential in deci-
sion making for treatment, and found that INSS and INPC were
signiﬁcant and independent predictors of prognosis in patients
who underwent stratiﬁcation of treatment. The study included
not only patients with clinically detected neuroblastoma but also
those identiﬁed by mass screening. In Japan, nearly 70% of neuro-
blastomas are detected by screening, usually at the age of 6 to 9
months (Tsuchida et al, 2000), hence the high incidence of infan-
tile neuroblastoma in the present study, and the data were analysed
thoroughly in the two age groups.
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